Equities research analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post ($0.17) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Halozyme Therapeutics’ earnings, with estimates ranging from ($0.22) to ($0.13). Halozyme Therapeutics posted earnings per share of ($0.16) in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Halozyme Therapeutics will report full year earnings of ($0.43) per share for the current fiscal year, with EPS estimates ranging from ($0.48) to ($0.39). For the next year, analysts expect that the firm will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.87) to ($0.23). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.01. The business had revenue of $56.95 million for the quarter, compared to analyst estimates of $67.80 million. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. Halozyme Therapeutics’s revenue was up 84.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) EPS.
Halozyme Therapeutics stock opened at $15.83 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market cap of $2.26 billion, a P/E ratio of -28.27 and a beta of 1.79. Halozyme Therapeutics has a 1-year low of $13.24 and a 1-year high of $19.94.
A number of institutional investors have recently bought and sold shares of HALO. Bank of Montreal Can increased its holdings in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 896 shares during the last quarter. Sageworth Trust Co increased its holdings in shares of Halozyme Therapeutics by 4,200.0% in the 1st quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 2,100 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $140,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Halozyme Therapeutics by 33.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 2,430 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $150,000. 83.33% of the stock is currently owned by institutional investors and hedge funds.
Halozyme Therapeutics Company Profile
There is no company description available for Halozyme Therapeutics Inc
Featured Article: What is range trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.